mPEG5-acetic acid

mPEG5-acetic acid is a versatile ADC linker intermediate frequently used in antibody-drug conjugate (ADC) development and targeted bioconjugation research. As an ADC linker building block, mPEG5-acetic acid provides a hydrophilic polyethylene glycol (PEG) spacer that improves solubility, reduces aggregation, and enhances pharmacokinetics of ADC payloads. Its terminal carboxylic acid group allows efficient conjugation with monoclonal antibodies or reactive ADC cytotoxins through amide bond formation. In ADC linker design, mPEG5-acetic acid supports site-specific bioconjugation strategies, maintaining antibody integrity while enabling controlled delivery of payloads to tumor cells.

In payload conjugation applications, mPEG5-acetic acid is compatible with a variety of ADC cytotoxins, including microtubule inhibitors, DNA-targeting agents, and other potent therapeutic payloads. Its PEG spacer improves the hydrophilicity and flexibility of the linker, reducing steric hindrance during antibody conjugation and improving overall stability of the ADC. Researchers can employ mPEG5-acetic acid to fine-tune linker length, optimize intracellular release, and enhance tumor-specific delivery. The reagent’s chemical versatility allows modular ADC linker construction, supporting both preclinical research and scalable industrial ADC production.

From an application perspective, mPEG5-acetic acid is widely used in oncology-focused ADC research, bioconjugation studies, and advanced drug delivery systems. Its hydrophilic PEG chain helps improve circulation time and reduce immunogenicity of ADC payloads. The carboxylic acid functional group enables predictable, reproducible conjugation under mild reaction conditions, preserving antibody function and antigen-binding specificity. By incorporating mPEG5-acetic acid into ADC linker design, developers can construct flexible, stable, and highly soluble ADC payload conjugates suitable for targeted cancer therapy and therapeutic bioconjugation applications.